Guardant Health Expands
Distribution of Guardant360, its breakthrough genomic cancer testing, in the
Middle East
Redwood City, California and Dubai
– September 22, 2016 – Guardant360, the leading comprehensive liquid biopsy
testing, will be available to more oncologists and their cancer patients in the
Middle East through a distribution agreement between Guardant Health and IPS
Genomix, the companies announced.
“We believe the great promise of
Guardant360 is its ability to democratize access to critical information about
a patient’s cancer,” said Helmy Eltoukhy, Guardant Health’s co-founder and CEO.
“Now oncologists across the United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Oman,
Lebanon, Egypt and Jordan will have access to the same comprehensive information
about the genomics of their patients’ solid tumors as doctors at the leading
U.S. cancer centers through a single blood draw.”
Guardant360 is the first and most
validated comprehensive liquid biopsy available commercially. It provides
comprehensive analysis of all major classes of somatic tumor alterations. The
test interrogates 70 cancer genes from a simple blood draw, with near-perfect
specificity and high sensitivity. Using Guardant Health's proprietary Digital
Sequencing technology, Guardant360 can detect cell-free DNA at mutant allele
fractions (MAF) as low as 0.1%, and will help match patients to targeted
therapies and access precision care through a simple blood test
IPS Genomix will handle distribution,
reimbursement, and will facilitate patient access for Guardant360 in The United
Arab Emirates, Saudi Arabia, Qatar, Kuwait, Oman, Lebanon, Egypt and Jordan.
Guardant Health will perform all testing at its CLIA-certified and
CAP-accredited laboratory in Redwood City, Calif.
“With more than 25 years of
experience bringing world-class medical products to doctors in the Middle East
and Africa, we aim to provide patients with the most effective and appropriate tools
in fighting cancer.” said Ahmed Yacout, Chairman and CEO of IPS Group. “We are excited
to help Guardant Health in this region through our dedicated personalized
medicine expert teams in the region and expect oncologists here will rapidly
adopt this exciting new technology.”
About Guardant Health
Guardant Health, headquartered in
Redwood City, Calif., is focused on developing breakthrough diagnostics that
can transform cancer from a silent killer into a manageable disease. Guardant
Health was founded in 2012 by a team of serial entrepreneurs with expertise in
next-generation sequencing, single-cell genomics, and cancer diagnostics. The
company has raised $200 million from leading venture capital firms and its
first product, Guardant360, came to market in 2014. The team is committed to
positively and significantly impacting patient health through technology that
addresses long-standing unmet needs in oncology.
About IPS Genomix
IPS Genomix was founded in 2013 by a group of
experts who have been in the healthcare domain for more than 25 years in the
Middle East and Africa territory. IPS Genomix partners with US and European
molecular diagnostic companies, to provide a diversification of genomic testing
services focused on improving patient care utilizing the latest technologies of
prognostic, predictive & personalized medicine. The treating physician can
then individualize the treatment of his patients to enhance the prevention
and/or treatment of certain conditions and diseases. Given the rapid evolution
of this particular field, IPS Genomix constantly incorporates new technology
platforms and assays to offer physicians and their patients with the most up to
date, reliable and cutting edge personalized medicine tools.